e-learning
resources
Barcelona 2013
Monday, 09.09.2013
COPD mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level
K. Gashynova (Dnipropetrovsk, Ukraine)
Source:
Annual Congress 2013 –COPD mechanisms
Session:
COPD mechanisms
Session type:
Thematic Poster Session
Number:
2151
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Gashynova (Dnipropetrovsk, Ukraine). COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level. Eur Respir J 2013; 42: Suppl. 57, 2151
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level
Source: Annual Congress 2012 - COPD exacerbation
Year: 2012
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014
Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Plasma surfactant protein D (SP-D) and comorbidity rate in patients with COPD
Source: International Congress 2014 – Predictors
Year: 2014
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts)
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE)
Source: International Congress 2019 – Exacerbations of airway diseases
Year: 2019
Plasma surfactant protein D (SP-D) and smoking status in patients with COPD
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI)
Source: Annual Congress 2013 –Lung infections: a clinical point of view
Year: 2013
COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level
Source: International Congress 2015 – COPD: notable points
Year: 2015
Effects of an acute exacerbation requiring hospitalisation (AE) on lung function, muscle force and serum IGF-I levels in male patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 564s
Year: 2002
Heterogeneity inside group D COPD patients: About 827 cases
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Intermediate and severe α
1
-antitrypsin deficiency: influence on plasma α
1
-antitrypsin, FEV
1
and risk of COPD. Three meta-anlyses
Source: Eur Respir J 2002; 20: Suppl. 38, 513s
Year: 2002
Correlation between extracellular heat shock protein 72 and clinical parameters including exhaled oxygen level in COPD
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation
Source: International Congress 2016 – Inflammatory biomarkers in airway diseases
Year: 2016
Clara cells protein 16 (CC-16) level correlates with hemoglobin level in COPD patients
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Fibrinogen and CRP biomarkers in patients with exacerbation of COPD group C and D
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept